Article Figures & Data
Figures
- Figure 1 Anti-Nfasc155 IgG4 Cross-Link Nfasc155 and Undergo Fab-Arm Exchange In Vitro
(A) Principle of Fab-arm exchange (FAE) and monospecificity assay. Reduced glutathione (GSH) favors FAE of monospecific IgG4 to generate bispecific IgG4. Monospecific antibodies cross-link untagged Nfasc155 with biotinylated Nfasc155. Bispecific antibodies are unable to cross-link these proteins. (B) Purified IgG4 from healthy controls (HC; n = 10), seronegative CIDP (CIDP−; n = 10) and Nfasc155+ autoimmune nodopathy (AN+; n = 10) were tested by ELISA against Nfasc155 and then incubated with a biotinylated Nfasc155 and revealed with streptavidin-HRP. IgG4 from HCs or seronegative patients did not cross-link Nfasc155. By contrast, IgG4 from Nfasc155+ patients cross-linked Nfasc155 (***p < 0.001 by one-way ANOVA followed by Bonferroni post hoc tests). The percentage of monospecific Nfasc155 antibodies correlated with the titers of anti-Nfasc155 IgG4. p Value, Spearman correlation coefficient (r), R square (R2), and 95% confidence band (dotted lines) are indicated on the graph. (C) To determine whether anti-Nfasc155 IgG4 can undergo FAE, IgG4 from Nfasc155+ patients (n = 9) were incubated with GSH in the absence (1:0) or presence of a 3-fold excess of HC IgG4 (1:3). The addition of GSH decreased IgG4 ability to cross-link Nfasc155. This effect was exacerbated by the addition of 3-fold excess of HC IgG4. The decrease in monospecific antibodies is shown on the right as ratio (**p < 0.005 compared with control condition in the absence of GSH or HC IgG4 using paired Student t tests). (D) As controls, IgG1 from Nfasc155+ patients (n = 7) were tested against Nfas155 with the monospecificity ELISA assay. Purified IgG1 cross-linked Nfasc155. GSH and 3-fold IgG4 excess did not affect IgG1-mediated cross-linking (p > 0.005 using paired Student t tests). Gray shades delineate positivity limit values. Bars represent mean and SEM, CIDP = chronic inflammatory demyelinating polyneuropathy; ns = nonsignificant; Nfasc155 = neurofascin-155.
- Figure 2 Fab-Arm Exchange Modulates the Ratio of κ:λ Light Chain in Nfasc155-Reactive IgG4
(A and B) The levels of λ and κ light chains of anti-Nfasc155 IgG4 were measured by ELISA against Nfasc155 in 10 reactive patients (A). The levels of λ (green dots) and κ (blue dots) light chains were also quantified by sandwich ELISA in the purified IgG4 fractions from healthy controls (n = 10), unreactive CIDP patients (CIDP−; n = 10), and reactive autoimmune nodopathy patients (AN+; n = 10) and were compared with those found in anti-Nfasc155 IgG4 (B). The levels of κ light chain strongly correlated with those of λ light chain in Nfasc155+ patients. No significant differences in the levels of λ and κ light chains were found between the groups (p > 0.01 by one-way ANOVA followed by Bonferroni post hoc tests). p Value, Spearman correlation coefficient (r), R square (R2), and 95% confidence band (dotted lines) are indicated on the graph. (C and D) IgG4 from Nfasc155+ patients (n = 10) were incubated with of a 3-fold excess of monoclonal IgG4/λ (C) or IgG4/κ (D) in the presence or absence of reduced glutathione (GSH). The levels of κ and λ light chains were then measured by ELISA against Nfasc155, and the ratio κ/λ (red dots) was calculated. Fab-arm exchange (FAE) with IgG4/λ significantly increased the levels of λ light chains and decreased the levels of κ light chains in anti-Nfasc155 IgG4 and resulted in a decrease of the κ/λ ratio. Reversely, FAE with FAE with IgG4/κ significantly increased the levels of κ light chains and decreased those of λ light chains in anti-Nfasc155 IgG4 and resulted in an increase of the κ/λ ratio (*p < 0.05; **p < 0.005; ***p < 0.001 compared with control condition in the absence of GSH using paired Student t tests). The percentage of increase or decrease of the κ/λ ratio following FAE (gray dots) with IgG4/λ or IgG4/κ was quantified for each patient. Changes in the κ/λ ratio were significantly different following FAE with IgG4/λ or IgG4/κ (***p < 0.001 using paired Student t tests). CIPD = chronic inflammatory demyelinating polyneuropathy; Nfasc155 = neurofascin-155.
- Figure 3 Bivalent F(ab’)2 From Nfasc155-Reactive IgG4 Abrogate Paranode Formation but Not Monovalent Fab
(A and B) New-born rat pups received an intraperitoneal injection of 250 µg of anti-Nfasc155 IgG4, Fab, or F(ab’)2 from patient AN1 (n = 4 animals for each condition and age). As controls, animals received 250 µg of IgG4 from healthy donors. Two days after injection, animals were killed, and sciatic nerve fibers were fixed. Teased sciatic nerve fibers were then immunolabeled for voltage-gated sodium channels (Nav; green) to label nodes and heminodes and for CASPR1 (red) to label paranodes. (C and D) The percentage of Nav clusters lacking CASPR1-positive paranodes (arrowheads) or with 1 or 2 flanking CASPR1 positive paranodes (double arrowheads) was quantified, as well as the paranodal length (D) (n = 100–200 nodes or paranodes for each condition). The injection of native IgG4 or F(ab’)2 fragments from patient AN1 strongly abrogated the formation of CASPR1-positive paranodes and resulted in a higher percentage of heminodes lacking paranodes (****p < 0.0001, ***p < 0.001, **p < 0.005, and *p < 0.05 by one-way ANOVA followed by Bonferroni post hoc tests). The mean length of paranodes was also shorter after treatment with native IgG4 or F(ab’)2 fragments reactive to Nfasc155 (****p < 0.0001 and ***p < 0.001 by one-way ANOVA followed by Bonferroni post hoc tests). By contrast, the injection of the monovalent Fab fragment of IgG4 did not affect the formation or the length of paranodes (G and H). Scale bar: 10 μm. Bars represent mean and SEM CASPR1 = contactin-associated protein 1; ns = nonsignificant; Nfasc155 = neurofascin-155.
- Figure 4 Bivalent Antibodies Cluster on the Schwann Cell Surface of Myelinated Fibers
(A–D) Rat sciatic nerve were incubated in vitro for 3 hours with control IgG4 (A) or with Nfasc155-reactive IgG4 (B), Fab fragment (C), or F(ab’)2 fragment (D) from patient AN1. Fibers were then immunostained for IgG (green) and contactin-1 (CNTN1; red) to label paranodes. By contrast to control IgG4, Nfasc155-reactive IgG4 accumulated at paranode vicinity (double arrowheads) and along the outer mesaxon (arrows). The cleavage into the Fab fragment inhibited IgG4 accumulation at the mesaxon and around paranodes (C). By contrast, the cleavage into the F(ab’)2 fragment did not alter the ability to aggregate at the mesaxon and paranode vicinity despite the absence of the Fc region (D). Scale bars: 10 μm. Nfasc155 = neurofascin-155.
- Figure 5 Fab-Arm Exchange Decreases the Pathogenicity of Nfasc155-Reactive IgG4
(A) Fab-arm exchange (FAE) was induced in vitro between IgG4 from patient AN1 and healthy donor IgG4. New-born rat pups were injected at birth with control IgG4 (250 µg per animal), IgG4 from patient AN1 (250 µg per animal), or swapped IgG4 from patient AN1 (FAE; 1 mg per animal) and killed after 2 days. Teased fibers were immunostained for voltage-gated sodium channels (Nav; green) and CASPR1 (red) (n = 4 animals for each condition and age). (B and C) The percentage of Nav clusters lacking CASPR1-positive paranodes (arrows) and Nav clusters with 1 or 2 flanking paranodes (double arrowheads) was counted in each group. The injection of native Nfasc155-reactive IgG4 reduced the formation of CASPR1-positive paranodes and significantly decreased the mean length of paranodes. By contrast, swapped reactive Nfasc155 IgG4 did not significantly affect paranode formation. Nonetheless, paranodal length was decreased in animals treated with swapped IgG4 (****p < 0.0001, ***p < 0.001, **p < 0.005, and *p < 0.05 by one-way ANOVA followed by Bonferroni post hoc tests) (n = 100–200 nodes or paranodes for each condition). Scale bars: 10 μm. Bars represent mean and SEM. CASPR1 = contactin-associated protein 1; ns = nonsignificant; Nfasc155 = neurofascin-155.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
